{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:45:54Z","timestamp":1772793954218,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00228-018-2549-7","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T15:32:28Z","timestamp":1536247948000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women"],"prefix":"10.1007","volume":"75","author":[{"given":"Anna","family":"Elgart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arik A.","family":"Zur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorit","family":"Mimrod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vered","family":"Dror","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Bar-Ilan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tjeerd","family":"Korver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Spiegelstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"key":"2549_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jns.2011.02.019","volume":"306","author":"W Bruck","year":"2011","unstructured":"Bruck W, Wegner C (2011) Insight into the mechanism of laquinimod action. J Neurol Sci 306:173\u2013179","journal-title":"J Neurol Sci"},{"issue":"11","key":"2549_CR2","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","volume":"366","author":"G Comi","year":"2012","unstructured":"Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca M, Filippi M, ALLEGRO Study Group (2012) Placebo-controlled trial of oral laquinimod in multiple sclerosis. N Engl J Med 366(11):1000\u20131009","journal-title":"N Engl J Med"},{"issue":"4","key":"2549_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","volume":"261","author":"TL Vollmer","year":"2014","unstructured":"Vollmer TL, Sorensen PS, Selmaj ZF, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL, BRAVO Study Group (2014) A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 261(4):773\u2013783","journal-title":"J Neurol"},{"issue":"8","key":"2549_CR4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/gutjnl-2014-307118","volume":"64","author":"G D\u2019Haens","year":"2015","unstructured":"D\u2019Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG, Laquinimod for Crohn\u2019s Disease Investigators (2015) A phase II study of laquinimod in Crohn\u2019s disease. Gut 64(8):1227\u20131235","journal-title":"Gut"},{"key":"2549_CR5","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1038\/s41598-017-04990-1","volume":"7","author":"G Ellrichmann","year":"2017","unstructured":"Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden MR, Sehr D, Winklhofer KF, Saft C, Gold R (2017) Laquinimod treatment in the R6\/2 mouse model. Sci Rep 7:4947. https:\/\/doi.org\/10.1038\/s41598-017-04990-1","journal-title":"Sci Rep"},{"key":"2549_CR6","doi-asserted-by":"publisher","first-page":"31652","DOI":"10.1038\/srep31652","volume":"6","author":"M Garcia-Miralles","year":"2016","unstructured":"Garcia-Miralles M, Hong X, Juin Tan L, Caron N, Huang Y, Toe XV et al (2016) Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep 6:31652. https:\/\/doi.org\/10.1038\/srep31652","journal-title":"Sci Rep"},{"key":"2549_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-801893-4.00003-1","volume":"144","author":"C Kay","year":"2017","unstructured":"Kay C, Hayden MR, Leavitt BR (2017) Epidemiology of Huntington disease. Handb Clin Neurol 144:31\u201346. https:\/\/doi.org\/10.1016\/B978-0-12-801893-4.00003-1","journal-title":"Handb Clin Neurol"},{"key":"2549_CR8","volume-title":"Clinical methods: the history, physical, and laboratory examinations","author":"RA Hatcher","year":"1990","unstructured":"Hatcher RA, Kowal D (1990) Birth control. In: Walker HK, Hall WD, Hurst JW (eds) Clinical methods: the history, physical, and laboratory examinations, 3rd edn. Butterworths, Boston Chapter 174. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK283","edition":"3"},{"issue":"1","key":"2549_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12974-017-0945-z","volume":"14","author":"T Ziemssen","year":"2017","unstructured":"Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N et al (2017) Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. J Neuroinflammation 14(1):172. https:\/\/doi.org\/10.1186\/s12974-017-0945-z","journal-title":"J Neuroinflammation"},{"issue":"3","key":"2549_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1586\/ecp.12.12","volume":"5","author":"W Br\u00fcck","year":"2012","unstructured":"Br\u00fcck W, Zamvil S (2012) Laquinimod, a once-daily oral drug in development for the treatment of relapsing\u2013remitting multiple sclerosis. Expert Rev Clin Pharmacol 5(3):245\u2013256","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2549_CR11","doi-asserted-by":"crossref","unstructured":"Spiegelstein O, Dorit Mimrod D, Rabinovich L, Eyal E, Sprenger C, Elgart A et al (2018) A thorough QT\/QTc study with laquinimod, a novel immunomodulator in development for multiple sclerosis and Huntington disease. Clin Pharmacol Drug Dev 0(0):1\u201318 online version","DOI":"10.1002\/cpdd.442"},{"key":"2549_CR12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1124\/dmd.104.002238","volume":"33","author":"H Tuvesson","year":"2005","unstructured":"Tuvesson H, Hallin I, Persson R, Sparre B, Gunnarsson PO, Seideg\u00e5rd J (2005) Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab Dispos 33:866\u2013872","journal-title":"Drug Metab Dispos"},{"key":"2549_CR13","doi-asserted-by":"publisher","first-page":"E6145","DOI":"10.1073\/pnas.1607843113","volume":"113","author":"J Kaye","year":"2016","unstructured":"Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, Grossman I, Knappertz V, Hayden MR, Laufer R (2016) Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 113:E6145\u2013E6152","journal-title":"Proc Natl Acad Sci USA"},{"key":"2549_CR14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.7705\/biomedica.v32i4.789","volume":"32","author":"I Moreno","year":"2012","unstructured":"Moreno I, Qui\u00f1ones L, Catal\u00e1n J, Miranda C, Roco \u00c1, Sasso J, Tamayo E, C\u00e1ceres D, Tchernitchin AN, Gaete L, Saavedra I (2012) Influence of CYP3A4\/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study. Biomedica 32:570\u2013577","journal-title":"Biomedica"},{"key":"2549_CR15","unstructured":"US Health and Human Services, FDA CDER (2012) Draft guidance for industry on drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations. https:\/\/www.gpo.fdsys\/granule\/FR-2012-02-21\/2012-3958 . Accessed 19 Jan 2018"},{"key":"2549_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.5414\/CP201675","volume":"50","author":"OJ David","year":"2012","unstructured":"David OJ, Ocwieja M, Meiser K, Emotte C, Jakab A, Wemer J et al (2012) Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results. Int J Clin Pharmacol Ther 50:540\u2013544","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2549_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40261-013-0068-y","volume":"33","author":"S Macha","year":"2013","unstructured":"Macha S, Mattheus M, Pinnetti S, Woerle HJ, Broedl UC (2013) Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Clin Drug Investig 33:351\u2013357","journal-title":"Clin Drug Investig"},{"key":"2549_CR18","first-page":"CD004861","volume":"3","author":"N Maitra","year":"2004","unstructured":"Maitra N, Kulier R, Bloemenkamp KW, Helmerhorst FM, G\u00fclmezoglu AM (2004) Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev 3:CD004861","journal-title":"Cochrane Database Syst Rev"},{"key":"2549_CR19","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1002\/rcm.2730","volume":"20","author":"CJ Sennbro","year":"2006","unstructured":"Sennbro CJ, Olin M, Edman K, Hansson G, Gunnarsson PO, Sevnsson LD (2006) Determination of the immunomodulator laquinimod in human plasma by liquid chromatography\/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling. Rapid Commun Mass Spectrom 20:3313\u20133318","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2549_CR20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0026-895X(25)13356-7","volume":"33","author":"FP Guengerich","year":"1988","unstructured":"Guengerich FP (1988) Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 33:500\u2013508","journal-title":"Mol Pharmacol"},{"key":"2549_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1042\/bj2670221","volume":"267","author":"SE Ball","year":"1990","unstructured":"Ball SE, Forrester LM, Wolf CR, Back D (1990) Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 alpha-ethinyloestradiol. Relative activities of rat and human liver enzymes. J Biochem 267:221\u2013226","journal-title":"J Biochem"},{"key":"2549_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1046\/j.1365-2125.1999.00081.x","volume":"48","author":"AP Li","year":"1999","unstructured":"Li AP, Hartman NR, Lu C, Collins JM, Strong JM (1999) Effects of cytochrome P450 inducers on 17\u03b1-ethinyloestradiol (EE2) conjugation by primary human hepatocytes. Br J Clin Pharmacol 48:733\u2013742","journal-title":"Br J Clin Pharmacol"},{"key":"2549_CR23","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1248\/bpb.27.1900","volume":"27","author":"T Shiraga","year":"2004","unstructured":"Shiraga T, Niwa T, Ohno Y, Kagayama A (2004) Interindividual variability in 2-hydroxylation, 3-sulfaction and 3-glucuronidation of ethynylestradiol in human liver. Biol Pharm Bull 27:1900\u20131906","journal-title":"Biol Pharm Bull"},{"key":"2549_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1155\/1999\/539376","volume":"10","author":"GG Zhanel","year":"1999","unstructured":"Zhanel GG, Siemens S, Slayter K, Mandell L (1999) Antibiotic and oral contraceptive drug interactions: is there a need for concern? Can J Infect Dis 10:429\u2013433","journal-title":"Can J Infect Dis"},{"key":"2549_CR25","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0190-9622(94)70127-X","volume":"30","author":"DM Miller","year":"1994","unstructured":"Miller DM, Helms SE, Brodell RT (1994) A practical approach to antibiotic treatment in women taking oral contraceptives. J Am Acad Dermatol 30:1008\u20131011","journal-title":"J Am Acad Dermatol"},{"key":"2549_CR26","unstructured":"Labeling for Combined Hormonal Contraceptives Guidance for Industry Draft 2017. https:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-drugs-gen\/documents\/document\/ucm590673.pdf . Accessed 5 Feb 2018"},{"key":"2549_CR27","unstructured":"ALESSE\u00ae 28 Tablets Alesse Package Insert. Wyeth Pharmaceuticals https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020683s004s006s007lbl.pdf . Accessed 4 April 2018"},{"key":"2549_CR28","unstructured":"Nizoral (ketoconazole) Tablets package insert (2013) Janssen Pharmaceuticals, USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018533s040lbl.pdf . Accessed 19 Jan 2018"},{"key":"2549_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.contraception.2012.01.010","volume":"86","author":"H Blode","year":"2012","unstructured":"Blode H, Zeun S, Parke S, Zimmermann T, Rohde B, Mellinger U, Kunz M (2012) Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. Contraception 86:337\u2013344","journal-title":"Contraception"},{"key":"2549_CR30","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration (2017) Center for Drug Evaluation and Research (CDER) Clinical Drug Interaction Studies \u2014 study design, data analysis, and clinical implications guidance for industry. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm292362.pdf . Accessed 10 Aug 2018"},{"key":"2549_CR31","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1124\/dmd.104.000182","volume":"32","author":"B Wang","year":"2004","unstructured":"Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE (2004) The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos 32:1209\u20131212","journal-title":"Drug Metab Dispos"},{"key":"2549_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","volume":"46","author":"H Zhang","year":"2007","unstructured":"Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z et al (2007) Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 46:133\u2013157","journal-title":"Clin Pharmacokinet"},{"key":"2549_CR33","doi-asserted-by":"publisher","first-page":"819","DOI":"10.4155\/cli.12.66","volume":"2","author":"DH Lee","year":"2012","unstructured":"Lee DH, Linker RA (2012) Clinical and experimental data on the use of laquinimod for the treatment of multiple sclerosis. Clin Invest 2:819\u2013824","journal-title":"Clin Invest"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2549-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2549-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2549-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T22:59:16Z","timestamp":1751842756000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2549-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["2549"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2549-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"13 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors AE, AZ, DM, VD, OBI and OS are employees of Teva Pharmaceuticals Ltd. who are sponsoring the clinical development of laquinimod for Huntington\u2019s disease. TK was a consultant for Teva Pharmaceutics at the time the study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was carried out in compliance with the Declaration of Helsinki and International Council on Harmonization (ICH) Good Clinical Practice (E6) Guidelines and applicable national and local laws and regulations. The study was initiated after receiving approval from Independent Ethics Committee (IEC) Ethikkommission der \u00c4rztekammer Nordrhein, D\u00fcsseldorf Germany, and from national or local regulations of the competent health authorities. All the subjects gave their written consent for voluntary participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving humans and informed consent"}}]}}